asparaginase: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
asparaginase: clinical details
Prescribing considerations
- Prescribe and administer only within an experienced haematology or oncology service with resuscitation facilities.
- Record the product name and batch number for biological traceability.
- Assess previous asparaginase exposure, hypersensitivity, pancreatitis, thrombosis, bleeding, hepatic disease and prothrombotic risk.
- Consider serum or plasma asparaginase activity when accelerated clearance, antibodies or silent inactivation are suspected; obtain expert advice before changing preparation.
- Older adults and people with relevant comorbidity may tolerate treatment less well.
Contraindications and cautions
- Hypersensitivity to asparaginase, a native non-pegylated E. coli asparaginase preparation or an excipient.
- Current pancreatitis.
- Severe hepatic impairment.
- Known pre-existing coagulopathy such as haemophilia.
- Previous pancreatitis, serious haemorrhage or serious thrombosis caused by asparaginase.
Monitoring
- Before treatment: bilirubin, hepatic transaminases and coagulation parameters.
- During treatment: liver tests, blood or urinary glucose, coagulation parameters, amylase, lipase, triglycerides and cholesterol.
- Monitor albumin and assess unexplained oedema.
- Assess immediately for hypersensitivity, pancreatitis, thrombosis, bleeding, hepatotoxicity, hyperglycaemia and neurological symptoms.
- Check ammonia for unexplained neurological symptoms or severe prolonged vomiting.
- Monitor for myelosuppression and infection within the combination regimen.
Clinical pharmacology
Spectrila is recombinant native E. coli asparaginase. It hydrolyses circulating asparagine and is distributed mainly within the intravascular compartment; as a protein enzyme, it is thought to undergo proteolytic degradation.
Formulation and product differences
- Spectrila is a recombinant, non-pegylated E. coli-derived powder for concentrate licensed for intravenous infusion only.
- Preparations differ by bacterial source, modification, pharmacokinetics and immunogenicity; switching should be specialist-led rather than treated as direct substitution.
- Clinical allergy or neutralising antibodies can reduce enzyme activity, sometimes without visible hypersensitivity.
asparaginase interactions
Treatment order and laboratory monitoring matter. Tell the team about all prescribed, non-prescribed and complementary products.
Vincristine
Toxicity may be additive, so specialists control the administration sequence.
Methotrexate
Asparagine depletion can alter its anticancer effect, so treatment order is protocol-controlled.
Cytarabine
Prior asparaginase exposure may reduce cytarabine activity, whereas the opposite sequence may be synergistic.
Glucocorticoids
Combined treatment may increase coagulation changes and thrombosis risk.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.